NAV

Eprinomectin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Eprinomectin
DrugBank Accession Number
DB11405
Background

Not Available

Type
Small Molecule
Groups
Vet approved
Structure
Similar Structures
Weight
Average: 900.116
Monoisotopic: 899.503106035
Chemical Formula
C49H73NO14
Synonyms
  • Eprinomectin
  • Eprinomectina
  • éprinomectine
  • Eprinomectinum
External IDs
  • MK 397
  • MK-397
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Eprinomectin.
AcalabrutinibThe serum concentration of Acalabrutinib can be increased when it is combined with Eprinomectin.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Eprinomectin.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Eprinomectin.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Eprinomectin.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Eprinex

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as macrolides and analogues. These are organic compounds containing a lactone ring of at least twelve members.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Macrolides and analogues
Sub Class
Not Available
Direct Parent
Macrolides and analogues
Alternative Parents
O-glycosyl compounds / Ketals / Monosaccharides / Pyrans / Oxanes / Acetamides / Tertiary alcohols / Oxolanes / Secondary alcohols / Secondary carboxylic acid amides
show 10 more
Substituents
Acetal / Acetamide / Alcohol / Aliphatic heteropolycyclic compound / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Carboxylic acid ester / Dialkyl ether / Ether
show 22 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
75KP30FD8O
CAS number
123997-26-2
InChI Key
WPNHOHPRXXCPRA-TVXIRPTOSA-N
InChI
InChI=1S/C49H73NO14/c1-25(2)43-28(5)17-18-48(64-43)23-35-20-34(63-48)16-15-27(4)44(26(3)13-12-14-33-24-57-46-42(52)29(6)19-36(47(53)60-35)49(33,46)54)61-40-22-38(56-11)45(31(8)59-40)62-39-21-37(55-10)41(30(7)58-39)50-32(9)51/h12-15,17-19,25-26,28,30-31,34-46,52,54H,16,20-24H2,1-11H3,(H,50,51)/b13-12-,27-15-,33-14-/t26-,28-,30-,31-,34+,35-,36-,37+,38-,39-,40-,41+,42+,43+,44-,45+,46+,48+,49+/m0/s1
IUPAC Name
N-[(2S,3R,4R,6S)-6-{[(2S,3R,4S,6R)-6-[(1'R,2S,4'S,5S,6R,8'R,10'Z,12'S,13'S,14'Z,16'Z,20'R,21'R,24'S)-21',24'-dihydroxy-5,11',13',22'-tetramethyl-6-(propan-2-yl)-5,6-dihydro-3',7',19'-trioxaspiro[pyran-2,6'-tetracyclo[15.6.1.1^{4,8}.0^{20,24}]pentacosane]-10',14',16',22'-tetraen-2'-oneoxy]-4-methoxy-2-methyloxan-3-yl]oxy}-4-methoxy-2-methyloxan-3-yl]acetamide
SMILES
[H]O[C@@H]1C(C)=C[C@@]2([H])C(=O)O[C@@]3([H])C[C@@]([H])(C\C=C(C)/[C@@H](O[C@H]4C[C@H](OC)[C@H](O[C@H]5C[C@@H](OC)[C@H](N([H])C(C)=O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C/C=C4/CO[C@@]1([H])[C@]24O[H])O[C@@]1(C3)O[C@H](C(C)C)[C@@H](C)C=C1

References

General References
  1. Zeng Z, Andrew NW: Characterization of eprinomectin N-deacetylase in rats. Drug Metab Dispos. 1999 Feb;27(2):269-73. [Article]
  2. Lespine A, Sutra JF, Dupuy J, Alvinerie M: Eprinomectin in goat: assessment of subcutaneous administration. Parasitol Res. 2003 Jan;89(2):120-2. Epub 2002 Sep 24. [Article]
  3. Halley BA, Winter R, Yoon S, Marley SE, Rehbein S: The environmental safety of eprinomectin to earthworms. Vet Parasitol. 2005 Mar 10;128(1-2):109-14. Epub 2004 Dec 21. [Article]
  4. Yazwinski TA, Johnson EG, Thompson DR, Drag MD, Zimmerman GL, Langholff WK, Holste JE, Eagleson JS: Nematocidal efficacy of eprinomectin, delivered topically, in naturally infected cattle. Am J Vet Res. 1997 Jun;58(6):612-4. [Article]
  5. Cramer LG, Pitt SR, Rehbein S, Gogolewski RP, Kunkle BN, Langhoff WK, Bond KG, Maciel AE: Persistent efficacy of topical eprinomectin against nematode parasites in cattle. Parasitol Res. 2000 Nov;86(11):944-6. [Article]
  6. Barth D, Hair JA, Kunkle BN, Langholff WK, Lowenstein M, Rehbein S, Smith LL, Eagleson JS, Kutzer E: Efficacy of eprinomectin against mange mites in cattle. Am J Vet Res. 1997 Nov;58(11):1257-9. [Article]
  7. Avcioglu H, Balkaya I: Efficacy of eprinomectin against Toxocara vitulorum in calves. Trop Anim Health Prod. 2011 Feb;43(2):283-6. doi: 10.1007/s11250-010-9699-7. Epub 2010 Oct 7. [Article]
  8. Rehbein S, Winter R, Visser M, Maciel AE, Marley SE: Chorioptic mange in dairy cattle: treatment with eprinomectin pour-on. Parasitol Res. 2005 Dec;98(1):21-5. Epub 2005 Oct 21. [Article]
  9. Holste JE, Colwell DD, Kumar R, Lloyd JE, Pinkall NP, Sierra MA, Waggoner JW, Langholff WK, Barrick RA, Eagleson JS: Efficacy of eprinomectin against Hypoderma spp in cattle. Am J Vet Res. 1998 Jan;59(1):56-8. [Article]
  10. Litskas VD, Karamanlis XN, Batzias GC, Kamarianos AP: Sorption of the antiparasitic drug eprinomectin in three soils. Chemosphere. 2011 Jan;82(2):193-8. doi: 10.1016/j.chemosphere.2010.10.024. Epub 2010 Nov 4. [Article]
KEGG Drug
D04037
ChemSpider
4953133
RxNav
1006619
ZINC
ZINC000306122586
Wikipedia
Eprinomectin

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00747 mg/mLALOGPS
logP3.9ALOGPS
logP5.12Chemaxon
logS-5.1ALOGPS
pKa (Strongest Acidic)12.49Chemaxon
pKa (Strongest Basic)-1.3Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count13Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area178.93 Å2Chemaxon
Rotatable Bond Count8Chemaxon
Refractivity237.68 m3·mol-1Chemaxon
Polarizability98.77 Å3Chemaxon
Number of Rings7Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0ue9-0307040039-b213f5f46538aee9b7af
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0gis-0408090180-8c91486b4909f5778e9a
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0zfr-0901020012-f683a31b640cfeefad96
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0mi5-6610060390-79c7e8d8b7b51220c04b
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0uxr-0900040132-5bc36eeafc61b5e4a21e
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-3901020350-ce7bd72bba2b42c31571
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Enzymes

Details1. Cytochrome P450 3A4
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [Article]

Drug created at February 25, 2016 18:27 / Updated at February 21, 2021 18:53